181 related articles for article (PubMed ID: 9074520)
1. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
3. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.
Bakker M; van der Graaf WT; Piers DA; Franssen EJ; Groen HJ; Smit EF; Kool W; Hollema H; Müller EA; De Vries EG
Anticancer Res; 1999; 19(3B):2349-53. PubMed ID: 10472354
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
7. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
8. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
11. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
12. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
13. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.
Liu Z; Stevenson GD; Barrett HH; Furenlid LR; Wilson DW; Kastis GA; Bettan M; Woolfenden JM
Nucl Med Biol; 2005 Aug; 32(6):573-83. PubMed ID: 16026704
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
15. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M
J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794
[TBL] [Abstract][Full Text] [Related]
16. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
[TBL] [Abstract][Full Text] [Related]
17. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
18. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
[TBL] [Abstract][Full Text] [Related]
19. Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients.
Del Vecchio S; Zannetti A; Ciarmiello A; Aloj L; Caracò C; Fonti R; Botti G; D'Aiuto G; Salvatore M
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):809-14. PubMed ID: 12029556
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
